J. Perales Pascual , H. Navarro Aznárez , A. López Pérez , T. Gracia-Cazaña , Y. Gilaberte Calzada , Mª R. Abad Sazatornil
{"title":"银屑病患者报告的疗效、依从性和满意度。","authors":"J. Perales Pascual , H. Navarro Aznárez , A. López Pérez , T. Gracia-Cazaña , Y. Gilaberte Calzada , Mª R. Abad Sazatornil","doi":"10.1016/j.ad.2024.05.021","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Patient-reported outcomes (PROs) are outcomes evaluated by patients based on their perception of their disease and treatment.</div></div><div><h3>Objectives</h3><div>Determine antipsoriatic treatment-related adherence, quality of life (QoL) and satisfaction.</div></div><div><h3>Materials and Methods</h3><div>We conducted an observational cross-sectional, prospective, and single-center study in which PROs surveys were conducted on adherence (Morisky-Green [MG] test), treatment satisfaction (Spanish Questionnaire of Treatment Satisfaction in Psoriasis [CESTEP]) and QoL (Skindex-29 and DLQI). Additional variables include: PASI, BSA. Statistical analysis: Jamovi®2.3.26.</div></div><div><h3>Results</h3><div>A total of 100 surveys were conducted. Based on the MG questionnaire, we found that 75% (75/100) of patients were adherent vs 94% (94/100) from the dispensation records. Regarding CESTEP, a mean score of 7.4<!--> <!-->±<!--> <!-->7.7 (close to maximum satisfaction 0) was obtained, while DLQI yielded a score of 2.6<!--> <!-->±<!--> <!-->4.6 (indicating a small effect on QoL), and SKINDEX-29 a score of 14.6<!--> <!-->±<!--> <!-->15.4 (68% indicating mild (< 5) or very mild (6-17) impact according to Nijsten et al.).</div><div>Based on CESTEP a p.Rho Spearman value of 0.338 (p<!--> <!-->=<!--> <!-->0.004) was obtained in relation to PASI when the study was conducted with a BSA of 0.255 (p<!--> <!-->=<!--> <!-->0.050), DLQI results of 0.508 (p <<!--> <!-->0.001) and Skindex-29 results of 0.397(p <<!--> <!-->0.001). At the time of the study, the correlation matrix between DLQI result and PASI was 0.365 (p<!--> <!-->=<!--> <!-->0.002) with a BSA of 0.347 (p<!--> <!-->=<!--> <!-->0.007). Skindex-29 results with PASI were 0.380 (p<!--> <!-->=<!--> <!-->0.001) and with BSA, 0.295 (p<!--> <!-->=<!--> <!-->0.022).</div></div><div><h3>Conclusions</h3><div>Patients on therapy exhibit a good QoL, high adherence and satisfaction with their treatment. A significant correlation was seen among satisfaction, QoL, and PASI-BSA at the time of the study.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"116 2","pages":"Pages 141-146"},"PeriodicalIF":3.8000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Resultados comunicados por el paciente, adherencia y satisfacción en pacientes con psoriasis\",\"authors\":\"J. Perales Pascual , H. Navarro Aznárez , A. López Pérez , T. Gracia-Cazaña , Y. Gilaberte Calzada , Mª R. Abad Sazatornil\",\"doi\":\"10.1016/j.ad.2024.05.021\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Patient-reported outcomes (PROs) are outcomes evaluated by patients based on their perception of their disease and treatment.</div></div><div><h3>Objectives</h3><div>Determine antipsoriatic treatment-related adherence, quality of life (QoL) and satisfaction.</div></div><div><h3>Materials and Methods</h3><div>We conducted an observational cross-sectional, prospective, and single-center study in which PROs surveys were conducted on adherence (Morisky-Green [MG] test), treatment satisfaction (Spanish Questionnaire of Treatment Satisfaction in Psoriasis [CESTEP]) and QoL (Skindex-29 and DLQI). Additional variables include: PASI, BSA. Statistical analysis: Jamovi®2.3.26.</div></div><div><h3>Results</h3><div>A total of 100 surveys were conducted. Based on the MG questionnaire, we found that 75% (75/100) of patients were adherent vs 94% (94/100) from the dispensation records. Regarding CESTEP, a mean score of 7.4<!--> <!-->±<!--> <!-->7.7 (close to maximum satisfaction 0) was obtained, while DLQI yielded a score of 2.6<!--> <!-->±<!--> <!-->4.6 (indicating a small effect on QoL), and SKINDEX-29 a score of 14.6<!--> <!-->±<!--> <!-->15.4 (68% indicating mild (< 5) or very mild (6-17) impact according to Nijsten et al.).</div><div>Based on CESTEP a p.Rho Spearman value of 0.338 (p<!--> <!-->=<!--> <!-->0.004) was obtained in relation to PASI when the study was conducted with a BSA of 0.255 (p<!--> <!-->=<!--> <!-->0.050), DLQI results of 0.508 (p <<!--> <!-->0.001) and Skindex-29 results of 0.397(p <<!--> <!-->0.001). At the time of the study, the correlation matrix between DLQI result and PASI was 0.365 (p<!--> <!-->=<!--> <!-->0.002) with a BSA of 0.347 (p<!--> <!-->=<!--> <!-->0.007). Skindex-29 results with PASI were 0.380 (p<!--> <!-->=<!--> <!-->0.001) and with BSA, 0.295 (p<!--> <!-->=<!--> <!-->0.022).</div></div><div><h3>Conclusions</h3><div>Patients on therapy exhibit a good QoL, high adherence and satisfaction with their treatment. A significant correlation was seen among satisfaction, QoL, and PASI-BSA at the time of the study.</div></div>\",\"PeriodicalId\":7173,\"journal\":{\"name\":\"Actas dermo-sifiliograficas\",\"volume\":\"116 2\",\"pages\":\"Pages 141-146\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Actas dermo-sifiliograficas\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0001731024004915\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Actas dermo-sifiliograficas","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0001731024004915","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Resultados comunicados por el paciente, adherencia y satisfacción en pacientes con psoriasis
Background
Patient-reported outcomes (PROs) are outcomes evaluated by patients based on their perception of their disease and treatment.
Objectives
Determine antipsoriatic treatment-related adherence, quality of life (QoL) and satisfaction.
Materials and Methods
We conducted an observational cross-sectional, prospective, and single-center study in which PROs surveys were conducted on adherence (Morisky-Green [MG] test), treatment satisfaction (Spanish Questionnaire of Treatment Satisfaction in Psoriasis [CESTEP]) and QoL (Skindex-29 and DLQI). Additional variables include: PASI, BSA. Statistical analysis: Jamovi®2.3.26.
Results
A total of 100 surveys were conducted. Based on the MG questionnaire, we found that 75% (75/100) of patients were adherent vs 94% (94/100) from the dispensation records. Regarding CESTEP, a mean score of 7.4 ± 7.7 (close to maximum satisfaction 0) was obtained, while DLQI yielded a score of 2.6 ± 4.6 (indicating a small effect on QoL), and SKINDEX-29 a score of 14.6 ± 15.4 (68% indicating mild (< 5) or very mild (6-17) impact according to Nijsten et al.).
Based on CESTEP a p.Rho Spearman value of 0.338 (p = 0.004) was obtained in relation to PASI when the study was conducted with a BSA of 0.255 (p = 0.050), DLQI results of 0.508 (p < 0.001) and Skindex-29 results of 0.397(p < 0.001). At the time of the study, the correlation matrix between DLQI result and PASI was 0.365 (p = 0.002) with a BSA of 0.347 (p = 0.007). Skindex-29 results with PASI were 0.380 (p = 0.001) and with BSA, 0.295 (p = 0.022).
Conclusions
Patients on therapy exhibit a good QoL, high adherence and satisfaction with their treatment. A significant correlation was seen among satisfaction, QoL, and PASI-BSA at the time of the study.
期刊介绍：
Actas Dermo-Sifiliográficas, publicación Oficial de la Academia Española de Dermatología y Venereología, es una revista de prestigio consolidado. Creada en 1909, es la revista mensual más antigua editada en España.En 2006 entró en Medline, y hoy resulta imprescindible para estar al día sobre la dermatología española y mundial.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
